Financial Review: Indivior (OTCMKTS:INVVY) and Tango Therapeutics (NASDAQ:TNGX)

Indivior (OTCMKTS:INVVY) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Indivior and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Tango Therapeutics	-299.88%	-44.35%	-27.63%

Risk and Volatility

Indivior has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Indivior shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 6.2% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Indivior and Tango Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Tango Therapeutics	$37.23 million	27.98	-$101.74 million	($1.13)	-8.63

Indivior has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Indivior and Tango Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	0	0	N/A
Tango Therapeutics	0	0	7	1	3.13

Tango Therapeutics has a consensus target price of $14.86, suggesting a potential upside of 52.38%. Given Tango Therapeutics’ higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Indivior.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.